Episodic Migraine

Enhanced Activation of the Spinal Trigeminal Nucleus in Chronic Migraine During Visual Stimulation

Enhanced Activation of the Spinal Trigeminal Nucleus in Chronic Migraine During Visual Stimulation

By

Patients with chronic migraine exposed to visual stimulation may have enhanced activity in the spinal trigeminal nucleus and the right superior colliculus compared with healthy individuals.

Erenumab Shows Promise in Treatment-Resistant Migraine

Erenumab Shows Promise in Treatment-Resistant Migraine

By

A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

Episodic Migraine-Related White Matter Hyperintensities Ipsilateral to Pain

Episodic Migraine-Related White Matter Hyperintensities Ipsilateral to Pain

By

Pain experienced by patients during episodic migraine is associated with the occurrence of white matter hyperintensities in the cerebral hemisphere ipsilateral to the pain side.

Episodic Migraines Possibly Prevented With Subcutaneous Galcanezumab

Episodic Migraines Possibly Prevented With Subcutaneous Galcanezumab

Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.

Migraine Frequency Reduced With Erenumab, Fremanezumab

Migraine Frequency Reduced With Erenumab, Fremanezumab

By

Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.

Using Stress to Predict Risk of Migraine Even Before Predromal Symptoms

Using Stress to Predict Risk of Migraine Even Before Predromal Symptoms

By

Among individuals diagnosed with episodic migraines, stressful events can accurately predict an individual's risk of a headache, even before the onset of prodromal symptoms.

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

By

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

Sign Up for Free e-Newsletters